- Oral
- Parenteral
- Others
Sepsis is a potentially life-threatening or medical emergency condition in which the immune systems overrides its response to an infection. Sepsis develops when the chemicals are released into the bloodstream which causes the cascade of eventsthat lead to the inflammation throughout the body. In most of the cases, it may lead to the septic shock, which is medical emergency. According to Center for Disease Control and Prevention (CDC), more than 1.5 million people get Sepsis each year in U.S. and 250,000 people die each year
Sepsis can quickly progress to septic shock and may lead to death. A number of medications are used to treat the Sepsis including painkillers, vasoactive medications to improve blood pressure, insulin, corticosteroids and antibiotics via IV route.
Key Developments:
- In December 2017, Adrenomed AG, announced today that the first patient with early septicshock has been dosed in the ADR-02 Phase-II study (AdrenOSS-2, NCT03085758)conducted in Germany, Belgium, France and the Netherlands.
- In January 2017, TiGenix NV announced that the first patient has been enrolled and treated in its Phase Ib/IIa clinical trial for Cx611 (SEPCELL) in the treatment of severe sepsis in community-acquired pneumonia (CAP).
Sepsis Disease Pipeline Drugs Assessment Dynamics
Sepsis Disease Pipeline Drugs Assessment report studies the various therapeutics under clinical development for Sepsis treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the Sepsis disease pipeline drugs development. This report studies the dynamics of the Sepsis Disease Pipeline Drugs i.e. drivers, challenges,and opportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on Sepsis disease pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.
Sepsis Disease Pipeline Drugs Assessment Segmentation
By Route of Administration
By Trial Phase,
- Preclinical Trials
- Phase 1
- Phase 2
- Phase 3
Frequently Asked Questions
2021 is the base year and 2028 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
| 1. Executive Summary |
| 2. Global Sepsis Disease Pipeline Drugs Assessment Market Introduction |
| 2.1.Global Sepsis Disease Pipeline Drugs Assessment Market - Taxonomy |
| 2.2.Global Sepsis Disease Pipeline Drugs Assessment Market - Definitions |
| 2.2.1.Route of Administration |
| 2.2.2.Trial Phase, |
| 3. Global Sepsis Disease Pipeline Drugs Assessment Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4. Global Sepsis Disease Pipeline Drugs Assessment Market Analysis, 2019 - 2023 and Forecast 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Sepsis Disease Pipeline Drugs Assessment Market By Route of Administration, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 5.1. Oral |
| 5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Parenteral |
| 5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Others |
| 5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 6. Global Sepsis Disease Pipeline Drugs Assessment Market By Trial Phase,, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million) |
| 6.1. Preclinical Trials |
| 6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Phase 1 |
| 6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Phase 2 |
| 6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 6.4. Phase 3 |
| 6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million) |
| 6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.4.3. Market Opportunity Analysis |
| 7. Competition Landscape |
| 7.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 7.2.1.Bristol-Myers Squibb (U.S.) |
| 7.2.2.Eisai Co., Ltd. (Japan) |
| 7.2.3.Shionogi & Company, Limited (Japan) |
| 7.2.4.Adrenomed AG (Germany) |
| 7.2.5.Ferring Holding SA (Switzerland) |
| 7.2.6.TiGenix (Belgium) |
| 8. Research Methodology |
| 9. Appendix and Abbreviations |
- Bristol-Myers Squibb (U.S.)
- Eisai Co., Ltd. (Japan)
- Shionogi & Company, Limited (Japan)
- Adrenomed AG (Germany)
- Ferring Holding SA (Switzerland)
- TiGenix (Belgium)